Matthew B. Klein - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol: PTCT
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 06 Jan 2026, 17:20:06 UTC
Previous filing: 02 Jan 2026
Next filing: 08 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Klein Matthew B.	CHIEF EXECUTIVE OFFICER, Director	C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN	/s/ Avraham S. Adler, Attorney-in-Fact	06 Jan 2026	0001808968

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PTCT	Common Stock	Award	$0	+63,000	+18%	$0.000000	405,132	02 Jan 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PTCT	Stock Option (Right to Buy)	Award	$0	+157,500		$0.000000	157,500	02 Jan 2026	Common Stock	157,500	$76.74	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
F2	Includes 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.
F3	This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.